Moderate dose-fractionated stereotactic body radiotherapy for medically Inoperab
PUBLISHED: 2015-11-26  348 total views, 1 today

Wei Jiang1, Jianyang Wang2, Jingbo Wang2, Jun Liang2Zhouguang Hui2, Xiaozhen Wang2, Zongmei Zhou2, Luhua Wang2

1Department of RadiationOncology, Cancer Hospital, Chinese Academy of Medical Sciences & Pekingunion       Medical College, 2Chinese Academy ofMedical Sciences & Peking union       Medical College, Cancer Hospital

 

Objective:To investigate the clinical outcomes andtoxicity of stereotactic body radiotherapy (SBRT) with amoderate dose fractionfor medically inoperable stage I non-small cell lung cancer (NSCLC).

Method:Patients treated with hypofractionated SBRT using fixed-field IMRT orvolumetric-modulated arc therapy at our hospital from June 2005 to December2013 were analyzed. The prescription doses ranged from 50 to 78Gy in total withfour to six Gy per fraction. The median follow-up period was 20 months. 

Result:A total of 65 patients were analyzed, including 43 primary NSCLC and 22patients with recurrent or secondary primary NSCLC. An objective response(complete responseor partial response) was achieved at six months in 84.6% ofpatients. The three-year local control rate was 90.8%. The Kaplan-Meierestimates of local failure-free, progression-free, overall survival andcancer-specific survival rates at three years were 90.3%, 64.3%, 69.1% and84.2%, respectively. The rate of symptomatic radiation pneumonitis was 16.9%,including one patient with Grade 5 who had a comorbidity. 

Conclusion: Favorablelocal control and outcome was achieved with a moderate SBRT regimen in patientswith inoperable stage I NSCLC with acceptable toxicity. A schedule of 6 Gy*12fractions may be promising, and a large-scale prospective study is in process.

 

Key Words: Stereotactic bodyradiotherapy  non-small cell lung


Copyright © 1998 - 2018 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

EMAIL:office@csco.org.cn

international@csco.org.cn

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)